Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02664324 · ClinicalTrials.gov registry record

MSPT Device Usability Study

A clinical trial of Multiple Sclerosis, sponsored by Biogen.

Completed
Registry status
60
Enrollment target
3
Study locations

NCT02664324: Completed study of Multiple Sclerosis, sponsored by Biogen.

NCT02664324 is a study of Multiple Sclerosis that has completed, run by Biogen. The registered enrollment target is 60 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02664324, a study of Multiple Sclerosis, has completed, sponsored by Biogen.

COMPLETED
Registry status
60 participants
Enrollment target
3
Study locations

Study Summary

The primary objective of this feasibility study is to evaluate the functionality (e.g., as defined by the primary endpoints) of the fully integrated Multiple Sclerosis Performance Test (MSPT) device, when used by unsupervised participants with MS, or related conditions, with a broad range of disability, in multi-clinical-care environments. Secondary objectives include: Participant perception of usability of device; Participant satisfaction with the device; Ascertain the impact of different clinical environments on device usability; Ascertain impact of assistive devices in usability of device; Ascertain functionality of Bluetooth remote as compared with manual timing.

Primary Outcome

The MSPT software tool builds upon previously validated measures comprising the Multiple Sclerosis Functional Composite (MSFC) that represents a comprehensive functional assessment of MS participants that include: MyHealth: MS -Patient demographic, health and medication information; NeuroQoL - Neurological Quality of Life test -Participant reported; PST Processing Speed Test- Measures mental processing speed; Contrast Sensitivity Test (CST)- 50cm vision test; MDT Manual Dexterity Test- 9 hole pe

Conditions Studied

Study Locations (3)

Maryland

  • Research Site - Baltimore

New York

  • Research Site - New York

Ohio

  • Research Site - Cleveland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2016-03
Est. Completion 2016-04
Biogen

334 total trials

What the finished NCT02664324 record still lists

NCT02664324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT02664324 reports a single indexed study location in Maryland, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT02664324 about?

NCT02664324 is a clinical study titled "MSPT Device Usability Study". The primary objective of this feasibility study is to evaluate the functionality (e.g., as defined by the primary endpoints) of the fully integrated Multiple Sclerosis Performance Test (MSPT) device, when used by unsupervised participants with MS, or related conditions, with a broad range of disabil...

What is the current status of trial NCT02664324?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2016-03. Estimated completion is 2016-04.

What conditions does trial NCT02664324 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT02664324?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02664324 being conducted?

This trial has 3 study locations across Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02664324's enrollment target sits among peer trials

60 159th of 315 higher than 146 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02664324, the US trial registry maintained by the National Library of Medicine. NCT02664324 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.